EPS for Genmab A/S (GNMSF) Expected At $0.72; BERGESEN WORLDWIDE OFFSHORE LTD COMM (BGSWF) Shorts Down By 16.45%

April 26, 2018 - By wolcottdaily

Genmab A/S (OTCMKTS:GNMSF) Logo

BERGESEN WORLDWIDE OFFSHORE LTD COMM (OTCMKTS:BGSWF) had a decrease of 16.45% in short interest. BGSWF’s SI was 96,500 shares in April as released by FINRA. Its down 16.45% from 115,500 shares previously. With 300 avg volume, 322 days are for BERGESEN WORLDWIDE OFFSHORE LTD COMM (OTCMKTS:BGSWF)’s short sellers to cover BGSWF’s short positions. It closed at $5.95 lastly. It is down 0.00% since April 26, 2017 and is . It has underperformed by 11.55% the S&P500.

Analysts expect Genmab A/S (OTCMKTS:GNMSF) to report $0.72 EPS on May, 9.They anticipate $0.68 EPS change or 1,700.00% from last quarter’s $0.04 EPS. GNMSF’s profit would be $44.08M giving it 71.18 P/E if the $0.72 EPS is correct. The stock increased 3.79% or $7.49 during the last trading session, reaching $205. About 122 shares traded. Genmab A/S (OTCMKTS:GNMSF) has 0.00% since April 26, 2017 and is . It has underperformed by 11.55% the S&P500.

BW Offshore Limited builds, owns, and operates gas and oil floating production, storage, and offloading vessels ; and floating, storage, and offloading vessels (FSOs) to the gas and oil industries in the Asia Pacific, the Americas, the European Union, and West Africa. The company has market cap of $1.11 billion. It also offers engineering, procurement, construction, and installation services; and lease and operation services of FPSO units. It has a 27.67 P/E ratio. As of March 8, 2016, the firm had a fleet of 14 FPSOs and 1 FSO.

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer in Denmark and internationally. The company has market cap of $12.55 billion. The firm markets Arzerra, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia ; and DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM). It has a 69.97 P/E ratio. The Company’s products under development include Ofatumumab to treat CLL and follicular lymphoma; Ofatumumab (OMB157) for relapsing remitting multiple sclerosis; and Daratumumab to treat MM, Non-Hodgkin's lymphoma, and solid tumors, as well as natural killer/T-cell lymphoma, nasal type.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>